[QUOTE=gvvianen;1091554]
Maar, wat een ingewikkelde taal, niet om door te komen. Ik houd me maar gewoon bij het boek Het Brein in je Buik, duidelijk en in gewone mensentaal geschreven, blijf verse voeding eten.[/QUOTE]
Ik vind het ook best lastig om door al die "lappen" tekst (meestal Engels) te lezen.:o
Ik houd mij ook bij verse (liefst biologisch) voeding. En probeer te luisteren naar mijn lichaam (darmen) hoe het reageert op de voeding.
N.a.v. jouw "boektip" heb ik dit boek aangevraagd bij de bieb.
Hopelijk leest het makkelijk "weg" ;)
MS en de relatie met de darmen
-
Marsei
Vitamine D verandert darmflora
Vitamine D verandert darmflora
[URL="https://bibliotheek.ortho.nl/10119/vita ... 4.facebook"][U]Vitamine D[/U][/URL] verandert darmflora
[QUOTE]Vitamine D-suppletie leidt tot een gunstiger samenstelling van de darmflora.[/QUOTE]
[URL="https://bibliotheek.ortho.nl/10119/vita ... 4.facebook"][U]Vitamine D[/U][/URL] verandert darmflora
[QUOTE]Vitamine D-suppletie leidt tot een gunstiger samenstelling van de darmflora.[/QUOTE]
-
Marsei
MS patients have a distinct gut microbiota compared to healthy controls
MS patients have a distinct gut microbiota compared to healthy controls
Multiple sclerosis patients have a [URL="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921909/"][U]distinct gut microbiota[/U][/URL] compared to healthy controls
[QUOTE][B]Abstract[/B]
Multiple sclerosis (MS) is an immune-mediated disease, the etiology of which involves both genetic and environmental factors. The exact nature of the environmental factors responsible for predisposition to MS remains elusive; however, it’s hypothesized that gastrointestinal microbiota might play an important role in pathogenesis of MS.
Therefore, this study was designed to investigate whether gut microbiota are altered in MS by comparing the fecal microbiota in relapsing remitting MS (RRMS) (n = 31) patients to that of age- and gender-matched healthy controls (n = 36).
Phylotype profiles of the gut microbial populations were generated using hypervariable tag sequencing of the V3–V5 region of the 16S ribosomal RNA gene.
Detailed fecal microbiome analyses revealed that MS patients had distinct microbial community profile compared to healthy controls. We observed an increased abundance of Psuedomonas, Mycoplana, Haemophilus, Blautia, and Dorea genera in MS patients, whereas control group showed [B]increased abundance of Parabacteroides, Adlercreutzia and Prevotella genera[/B].
Thus our study is consistent with the hypothesis that MS patients have gut microbial dysbiosis and further study is needed to better understand their role in the etiopathogenesis of MS.[/QUOTE]
Multiple sclerosis patients have a [URL="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921909/"][U]distinct gut microbiota[/U][/URL] compared to healthy controls
[QUOTE][B]Abstract[/B]
Multiple sclerosis (MS) is an immune-mediated disease, the etiology of which involves both genetic and environmental factors. The exact nature of the environmental factors responsible for predisposition to MS remains elusive; however, it’s hypothesized that gastrointestinal microbiota might play an important role in pathogenesis of MS.
Therefore, this study was designed to investigate whether gut microbiota are altered in MS by comparing the fecal microbiota in relapsing remitting MS (RRMS) (n = 31) patients to that of age- and gender-matched healthy controls (n = 36).
Phylotype profiles of the gut microbial populations were generated using hypervariable tag sequencing of the V3–V5 region of the 16S ribosomal RNA gene.
Detailed fecal microbiome analyses revealed that MS patients had distinct microbial community profile compared to healthy controls. We observed an increased abundance of Psuedomonas, Mycoplana, Haemophilus, Blautia, and Dorea genera in MS patients, whereas control group showed [B]increased abundance of Parabacteroides, Adlercreutzia and Prevotella genera[/B].
Thus our study is consistent with the hypothesis that MS patients have gut microbial dysbiosis and further study is needed to better understand their role in the etiopathogenesis of MS.[/QUOTE]
-
Marsei
Collection Gut-brain axis
Collection Gut-brain axis
Collection [URL="https://www.nature.com/collections/dyhbndhpzv"][U]Gut-brain axis[/U][/URL]
[QUOTE]
It is becoming increasingly evident that bidirectional signalling exists between the gastrointestinal tract and the brain, often involving the gut microbiota. This relationship, commonly dubbed the gut–brain axis (or the microbiota–gut–brain axis), involves various afferent and efferent pathways such as the vagus nerve and the hypothalamic-pituitary-adrenal pathway to regulate aspects of homeostasis such as satiety and hunger, and inflammation. Disruption of the gut–brain axis has been shown to be involved in the pathogenesis of a diverse range of diseases, including Parkinson disease and irritable bowel syndrome. Although the majority of data to-date is from animal models, this emerging area of research is evolving quickly and with promising translational value.
This collections brings together Research, Reviews and News from across the Nature Research journals and presents a selection of articles covering key aspects of the gut–brain axis including immune, neuroendocrine and neural factors. The content brought together in this collection has been published within the past 2 years in Nature Reviews Gastroenterology & Hepatology, Nature, Nature Communications, Nature Immunology, Nature Medicine, Nature Microbiology, Nature Neuroscience, Nature Outlook, Nature Reviews Disease Primers, Nature Reviews Endocrinology, Nature Reviews Microbiology, Nature Reviews Neurology, Nature Reviews Neuroscience, Nature Reviews Urology and Scientific Reports.[/QUOTE]
Collection [URL="https://www.nature.com/collections/dyhbndhpzv"][U]Gut-brain axis[/U][/URL]
[QUOTE]
It is becoming increasingly evident that bidirectional signalling exists between the gastrointestinal tract and the brain, often involving the gut microbiota. This relationship, commonly dubbed the gut–brain axis (or the microbiota–gut–brain axis), involves various afferent and efferent pathways such as the vagus nerve and the hypothalamic-pituitary-adrenal pathway to regulate aspects of homeostasis such as satiety and hunger, and inflammation. Disruption of the gut–brain axis has been shown to be involved in the pathogenesis of a diverse range of diseases, including Parkinson disease and irritable bowel syndrome. Although the majority of data to-date is from animal models, this emerging area of research is evolving quickly and with promising translational value.
This collections brings together Research, Reviews and News from across the Nature Research journals and presents a selection of articles covering key aspects of the gut–brain axis including immune, neuroendocrine and neural factors. The content brought together in this collection has been published within the past 2 years in Nature Reviews Gastroenterology & Hepatology, Nature, Nature Communications, Nature Immunology, Nature Medicine, Nature Microbiology, Nature Neuroscience, Nature Outlook, Nature Reviews Disease Primers, Nature Reviews Endocrinology, Nature Reviews Microbiology, Nature Reviews Neurology, Nature Reviews Neuroscience, Nature Reviews Urology and Scientific Reports.[/QUOTE]
-
Marsei
Gut Microbes Could Actually Be Triggering Relapses of Multiple Sclerosis
Gut Microbes Could Actually Be Triggering Relapses of Multiple Sclerosis
[URL="https://www.sciencealert.com/multiple-s ... t-microbes"][U]Gut Microbes[/U][/URL] Could Actually Be Triggering Relapses of Multiple Sclerosis
[QUOTE]
Several previous studies have identified microbiome differences between MS patients and healthy people, but new studies by teams at the University of California, San Francisco and the Max Planck Institute of Neurobiology in Germany have identified how the different gut microbiome may play a role.
In the University of California study, led by geneticist Sergio Baranzini, two genera of bacteria, Acinetobacter and Akkermansia, were found to be four times more abundant in MS patients than healthy people.
They also showed that a genus of bacterium called Parabacteroides is four times more abundant in healthy people than MS patients.
Previous studies had already shown that Acinetobacter and Akkermansia were more abundant in MS patients, and Parabacteroides more abundant in healthy people.
Baranzini's team wasn't simply trying to identify microbiome differences. They were trying to see what those differences mean. So they put a type of immune cell that transforms based on the threat it encounters in contact with Acinetobacter and Akkermansia.
These cells transformed into a type of T helper cells, which trigger inflammation as a mechanism for fighting infection. Moreover, Acinetobacter slowed the production of regulatory T cells, which suppress the immune response.
These regulatory T cells are very helpful for autoimmune patients, so limiting their production while accelerating production of cells that cause inflammation could exacerbate relapses.
To observe this, they transferred the bacteria to healthy mice and induced brain inflammation. Within 20 days, the mice had developed severe brain inflammation, compared to mice who had had gut bacteria transferred from healthy people. These control mice "didn't get nearly as sick," Baranzini said.
The second study, led by Gurumoorthy Krishnamoorthy and Hartmut Wekerle, looked at 34 sets of identical twins between the ages of 21 and 63, where only one twin had developed MS.
Again, they found that Akkermansia was more abundant in the twins with MS.
The took the microbiome from each of the 68 twins and transplanted them into mice predisposed to develop an autoimmune disease similar to MS.
After 12 weeks, they found mice transplanted with the MS twins' microbiome were three times more likely to develop a brain inflammation than those who were transplanted with the healthy microbiome.
Both studies had small sample sizes, and, Baranzini notes, it's too early to be thinking about potential treatments based on the information. However, both studies demonstrate that there is more to be learned from studying the microbiome in relation to multiple sclerosis.
"Our results," the University of California researchers wrote in their paper, "expand the knowledge of the microbial regulation of immunity and may provide a basis for the development of microbiome-based therapeutics in autoimmune diseases."[/QUOTE]
[URL="https://www.sciencealert.com/multiple-s ... t-microbes"][U]Gut Microbes[/U][/URL] Could Actually Be Triggering Relapses of Multiple Sclerosis
[QUOTE]
Several previous studies have identified microbiome differences between MS patients and healthy people, but new studies by teams at the University of California, San Francisco and the Max Planck Institute of Neurobiology in Germany have identified how the different gut microbiome may play a role.
In the University of California study, led by geneticist Sergio Baranzini, two genera of bacteria, Acinetobacter and Akkermansia, were found to be four times more abundant in MS patients than healthy people.
They also showed that a genus of bacterium called Parabacteroides is four times more abundant in healthy people than MS patients.
Previous studies had already shown that Acinetobacter and Akkermansia were more abundant in MS patients, and Parabacteroides more abundant in healthy people.
Baranzini's team wasn't simply trying to identify microbiome differences. They were trying to see what those differences mean. So they put a type of immune cell that transforms based on the threat it encounters in contact with Acinetobacter and Akkermansia.
These cells transformed into a type of T helper cells, which trigger inflammation as a mechanism for fighting infection. Moreover, Acinetobacter slowed the production of regulatory T cells, which suppress the immune response.
These regulatory T cells are very helpful for autoimmune patients, so limiting their production while accelerating production of cells that cause inflammation could exacerbate relapses.
To observe this, they transferred the bacteria to healthy mice and induced brain inflammation. Within 20 days, the mice had developed severe brain inflammation, compared to mice who had had gut bacteria transferred from healthy people. These control mice "didn't get nearly as sick," Baranzini said.
The second study, led by Gurumoorthy Krishnamoorthy and Hartmut Wekerle, looked at 34 sets of identical twins between the ages of 21 and 63, where only one twin had developed MS.
Again, they found that Akkermansia was more abundant in the twins with MS.
The took the microbiome from each of the 68 twins and transplanted them into mice predisposed to develop an autoimmune disease similar to MS.
After 12 weeks, they found mice transplanted with the MS twins' microbiome were three times more likely to develop a brain inflammation than those who were transplanted with the healthy microbiome.
Both studies had small sample sizes, and, Baranzini notes, it's too early to be thinking about potential treatments based on the information. However, both studies demonstrate that there is more to be learned from studying the microbiome in relation to multiple sclerosis.
"Our results," the University of California researchers wrote in their paper, "expand the knowledge of the microbial regulation of immunity and may provide a basis for the development of microbiome-based therapeutics in autoimmune diseases."[/QUOTE]
-
Marsei
Probiotics Consumption May Improve Certain Disease Parameters in MS Patients
Probiotics Consumption May Improve Certain Disease Parameters in MS Patients
[URL="https://multiplesclerosisnewstoday.com/ ... -suggests/"][U]Probiotics Consumption[/U][/URL] May Improve Certain Disease Parameters in MS Patients, Study Suggests
[QUOTE]Probiotics may improve the health of people with multiple sclerosis (MS) by reducing disability and improving inflammatory and metabolic parameters, an Iranian study shows.
[/QUOTE]
[QUOTE]
The probiotic contained the healthy bacteria Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum and Lactobacillus fermentum. Researchers measured patients’ health parameters and disability scores at baseline and after treatment.
The results showed that probiotic intake after 12 weeks improved MS patients’ disability scores (assessed by the expanded disability status scale, EDSS) when compared to placebo controls. Although this improvement was statistically significant, it was not clinically significant — which is defined as a change of 1.0 point or more at EDSS levels less than 5.5, or 0.5 point or more at EDSS levels greater than 5.5).
Moreover, benefits were also detected in several mental health parameters – Beck Depression Inventory, general health questionnaire-28 (GHQ-28), depression anxiety and stress scale.
Consuming probiotic capsules also significantly decreased insulin levels and high-density lipoprotein (HDL) cholesterol in circulation, researchers also found. It also lowered certain markers of inflammation and oxidative stress, such as serum high-sensitivity C-reactive protein (hs-CRP) and malondialdehyde (MDA).
“Our study demonstrated that the use of probiotic capsule for 12 weeks among subjects with MS had favorable effects on EDSS, parameters of mental health, inflammatory factors, markers of insulin resistance, HDL-, total/HDL-cholesterol and MDA levels,” the team concluded.[/QUOTE]
[URL="https://multiplesclerosisnewstoday.com/ ... -suggests/"][U]Probiotics Consumption[/U][/URL] May Improve Certain Disease Parameters in MS Patients, Study Suggests
[QUOTE]Probiotics may improve the health of people with multiple sclerosis (MS) by reducing disability and improving inflammatory and metabolic parameters, an Iranian study shows.
[/QUOTE]
[QUOTE]
The probiotic contained the healthy bacteria Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum and Lactobacillus fermentum. Researchers measured patients’ health parameters and disability scores at baseline and after treatment.
The results showed that probiotic intake after 12 weeks improved MS patients’ disability scores (assessed by the expanded disability status scale, EDSS) when compared to placebo controls. Although this improvement was statistically significant, it was not clinically significant — which is defined as a change of 1.0 point or more at EDSS levels less than 5.5, or 0.5 point or more at EDSS levels greater than 5.5).
Moreover, benefits were also detected in several mental health parameters – Beck Depression Inventory, general health questionnaire-28 (GHQ-28), depression anxiety and stress scale.
Consuming probiotic capsules also significantly decreased insulin levels and high-density lipoprotein (HDL) cholesterol in circulation, researchers also found. It also lowered certain markers of inflammation and oxidative stress, such as serum high-sensitivity C-reactive protein (hs-CRP) and malondialdehyde (MDA).
“Our study demonstrated that the use of probiotic capsule for 12 weeks among subjects with MS had favorable effects on EDSS, parameters of mental health, inflammatory factors, markers of insulin resistance, HDL-, total/HDL-cholesterol and MDA levels,” the team concluded.[/QUOTE]
-
Marsei
One More Small Piece of the Puzzle on the Role of Gut Micro-organisms in MS
One More Small Piece of the Puzzle on the Role of Gut Micro-organisms in MS
One More Small Piece of the Puzzle on the [URL="https://multiplesclerosisnewstoday.com/ ... 9-71296681"][U]Role of Gut Micro-organisms[/U][/URL] in MS
[QUOTE]Researchers found a significant increase in some types of gut bacteria and lower levels of an anti-inflammatory factor in untreated multiple sclerosis twins.
The study offered working evidence that components of gut microbiota contribute to autoimmune diseases like MS.[/QUOTE]
One More Small Piece of the Puzzle on the [URL="https://multiplesclerosisnewstoday.com/ ... 9-71296681"][U]Role of Gut Micro-organisms[/U][/URL] in MS
[QUOTE]Researchers found a significant increase in some types of gut bacteria and lower levels of an anti-inflammatory factor in untreated multiple sclerosis twins.
The study offered working evidence that components of gut microbiota contribute to autoimmune diseases like MS.[/QUOTE]
-
Marsei
Fecal transplant and MS
Fecal transplant and MS
Van Ashton Embry op FB:
[QUOTE]Fecal transplant and MS -
There are a lot of data that indicate one of the causal factors of MS is an altered gut flora. One of the strategies to correct this is a fecal transplant which introduces a healthy gut flora.
At the upcoming ECTRIMS MS conference (in Paris!), University of Calgary researchers report a case history of a woman with SPMS who was steadily declining. Because of a very serious gut infection, she had a fecal transplant in 2006 which saved her life. The researchers note that “Between 2007 and 2017 progression of her MS completely stabilized, even slightly improved. She continues to use a cane but only intermittently. Her Modified Multiple Sclerosis Functional Composite (MSFC) also improved.”
The one bothersome aspect of this good news story is that the U of C researchers have not followed up this major observation over the past 10 years. A real scientist would be organizing a clinical trial on the value of fecal transplant for MS after a maximum of 3 years of watching their patient improve. However, one of the researchers is “on the take” from the drug companies and one can only wonder if that influenced such a lack of enthusiasm for testing a non-drug, but potentially effective, therapy.
Furthermore, the U of C researchers at the same time were testing an antibiotic, which wrecks havoc on the gut flora, for those with an initial CNS immune attack (CIS). Notably, and not surprisingly, this study showed the antibiotic was of no value by 2 years.
To end with good news, a researcher at Western University has just started to populate a clinical [URL="https://clinicaltrials.gov/ct2/show/record/NCT03183869"][U]trial[/U][/URL] to test the safety of a fecal transplant for R-R MS. This restores my faith there are MS neurologists out there who put the health of their patients above all else.[/QUOTE]
Van Ashton Embry op FB:
[QUOTE]Fecal transplant and MS -
There are a lot of data that indicate one of the causal factors of MS is an altered gut flora. One of the strategies to correct this is a fecal transplant which introduces a healthy gut flora.
At the upcoming ECTRIMS MS conference (in Paris!), University of Calgary researchers report a case history of a woman with SPMS who was steadily declining. Because of a very serious gut infection, she had a fecal transplant in 2006 which saved her life. The researchers note that “Between 2007 and 2017 progression of her MS completely stabilized, even slightly improved. She continues to use a cane but only intermittently. Her Modified Multiple Sclerosis Functional Composite (MSFC) also improved.”
The one bothersome aspect of this good news story is that the U of C researchers have not followed up this major observation over the past 10 years. A real scientist would be organizing a clinical trial on the value of fecal transplant for MS after a maximum of 3 years of watching their patient improve. However, one of the researchers is “on the take” from the drug companies and one can only wonder if that influenced such a lack of enthusiasm for testing a non-drug, but potentially effective, therapy.
Furthermore, the U of C researchers at the same time were testing an antibiotic, which wrecks havoc on the gut flora, for those with an initial CNS immune attack (CIS). Notably, and not surprisingly, this study showed the antibiotic was of no value by 2 years.
To end with good news, a researcher at Western University has just started to populate a clinical [URL="https://clinicaltrials.gov/ct2/show/record/NCT03183869"][U]trial[/U][/URL] to test the safety of a fecal transplant for R-R MS. This restores my faith there are MS neurologists out there who put the health of their patients above all else.[/QUOTE]
-
Marsei
Immunological and Clinical Effect of Diet Modulation of the Gut Microbiome in Multipl
Immunological and Clinical Effect of Diet Modulation of the Gut Microbiome in Multipl
Immunological and Clinical Effect of Diet Modulation of the [URL="https://www.msweb.nl/forum/showpost.php ... tcount=358"][U]Gut Microbiome[/U][/URL] in Multiple Sclerosis Patients: A Pilot Study
Immunological and Clinical Effect of Diet Modulation of the [URL="https://www.msweb.nl/forum/showpost.php ... tcount=358"][U]Gut Microbiome[/U][/URL] in Multiple Sclerosis Patients: A Pilot Study